Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of GRIFFIN After 24 Months of Maintenance (AFT-29)
- Citation:
- Blood vol 138 (Supplement 1) 79
- Meeting Instance:
- ASH 2021
- Year:
- 2021
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- AFT
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Long-Term-Followup
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 3854
- Pharmas:
- Jansen Oncology
- Grants:
- Corr. Author:
- Authors:
- Jacob Laubach Johnathan L. Kaufman Douglas W. Sborov Brandi Reeves Cesar Rodriguez Ajai Chari Rebecca Silbermann Luciano J. Costa Larry D. Anderson Jr. Nitya Nathwani Nina Shah Yvonne A. Efebera Sarah A. Holstein Caitlin Costello Andrzej Jakubowiak Tanya M. Wildes Robert Z. Orlowski Kenneth H. Shain Andrew J. Cowan Huiling Pei Annelore Cortoos Sharmila Patel Blake Bartlett Jessica Vermeulen Thomas S. Lin Paul G. Richardson Peter M. Voorhees
- Networks:
- CA043, CA249, CA824, FL065, LAPS-AL002, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-OH007, LAPS-TX011, LAPS-TX035, LAPS-UT003, NC002, NE003, NEWMEXICO, OH008, OR013
- Study
- AFT-29 (GRIFFIN)
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: